Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, LG Paz-Ares, JF Vansteenkiste, MC Garassino, R Hui, X Quantin, A Rimner, YL Wu, M Ozguroglu, KH Lee, T Kato, M de Wit, E Macpherson, M Newton, P Thiyagarajah, SJ Antonia

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Number of pages3
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2021

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Cite this